Berinert

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Berinert
Generic name
HUMAN C1-ESTERASE INHIBITOR
Manufacturer
CSL Behring GmbH
Product type
PLASMA DERIVATIVE
SPL set ID
8ea0c7fe-da9d-4218-a080-0509e09bedc6
SPL ID
6f3826cd-77fd-4ae0-909c-66a91dbe5f72
Version
33
Effective date
2021-09-21
Source export date
2026-11-13
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:32:50

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions may occur. Epinephrine should be immediately available to treat any acute severe hypersensitivity reactions following discontinuation of administration. ( 5.1 ) Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products, including BERINERT, following administration in patients with HAE. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Benefits of treatment of HAE attacks should be weighed against the risks of TE events in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after BERINERT administration. TE events have also been reported following administration of a C1 Esterase Inhibitor (Human) product when used for unapproved indications at higher than recommended doses. 1 ( 5.2 ) Because BERINERT is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.3 ) Laryngeal HAE attacks: Following self-administration of BERINERT for laryngeal HAE attacks, advise patients to immediately seek medical attention. ( 5.4 ) 5.1 Hypersensitivity Severe hypersensitivity reactions may occur. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reaction [see Patient Counseling Information (17) ]. The signs and symptoms of hypersensitivity reactions may include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis during or after injection of BERINERT. Because hypersensitivity reactions may have symptoms similar to HAE attacks, treatment methods should be carefully considered. In case of suspected hypersensitivity, immediately discontinue administration of BERINERT and institute appropriate treatment. 5.2 Thromboembolic Events Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products, including BERINERT, following administration in patients with HAE. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Benefits of treatment of HAE attacks should be weighed against the risks of TE events in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after BERINERT administration. TE events have also been reported following administration of a C1 Esterase Inhibitor (Human) product when used for unapproved indications at higher than recommended doses 1,2 [see Overdosage (10) and Nonclinical Toxicology (13.2) ] . 5.3 Transmissible Infectious Agents Because BERINERT is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been minimized by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by processes demonstrated to inactivate and/or remove a wide range of viruses [see Description (11) ] . Despite these measures, such products may still potentially transmit disease and there is also the possibility that unknown infectious agents may be present in such products. However, since implementation of these measures, no case reports on suspected transmission of viruses have demonstrated a causal relationship to the administration of BERINERT. All infections thought by a physician possibly to have been transmitted by BERINERT should be reported by lot number, by the physician, or other healthcare provider to the CSL Behring Pharmacovigilance Department at 1-866-915-6958. 5.4 Laryngeal HAE Attacks Given the potential for airway obstruction during acute laryngeal HAE attacks, patients self-administering BERINERT should be advised to immediately seek medical attention in an appropriate healthcare facility after treatment with BERINERT.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most serious adverse reaction reported in subjects enrolled in clinical studies who received BERINERT was an increase in the severity of pain associated with HAE. The most common adverse reaction reported in greater than 4% of the subjects and greater than placebo among subjects who received BERINERT in the placebo-controlled clinical trial was dysgeusia. The most serious adverse reaction reported in subjects who received BERINERT was an increase in the severity of pain associated with HAE. ( 6.1 ) The most common adverse reaction reported in greater than 4% of the subjects and greater than placebo among subjects who received BERINERT in the placebo-controlled clinical trial was dysgeusia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Placebo-controlled Clinical Study In the placebo-controlled clinical study, referred to as the randomized clinical trial (RCT) [see Clinical Studies (14) ] , 124 subjects experiencing an acute moderate to severe abdominal or facial HAE attack were treated with BERINERT (either a 10 IU per kg body weight or a 20 IU per kg body weight dose), or placebo (physiological saline solution). The treatment-emergent serious adverse reactions/events that occurred in 5 subjects in the RCT were laryngeal edema, facial HAE attacks with laryngeal edema, swelling (shoulder and chest), exacerbation of hereditary angioedema, and laryngospasm. After initial infusion or rescue Medication treatment with BERINERT versus placebo, in the intent-to-treat population only one adverse reaction was reported in greater than one subject in either treatment group, at a frequency higher than placebo: dysgeusia was reported within 4 hours of infusion of BERINERT versus placebo (2/43, 4.7% vs. 0/42, 0%) and up to 72 hours (2/43, 4.7% vs. 1/42, 2.4%). Because more subjects in the placebo group than in the BERINERT group received rescue treatment, the median observation period in this analysis for subjects randomized to placebo was slightly longer than for subjects randomized to receive BERINERT. Subjects were tested at baseline and after 3 months for possible exposure to Parvovirus B19, hepatitis B, hepatitis C, and HIV-1 and HIV-2. No subject who underwent testing evidenced seroconversion or treatment-emergent positive polymerase chain reaction testing for these pathogens. Open-Label Extension Study In the safety analysis of the open-label extension study, 57 subjects with 1085 acute moderate to severe abdominal, facial, peripheral, and laryngeal HAE attacks received a 20 IU/kg body weight dose of BERINERT [see Clinical Studies (14) ] . This study provides additional safety data in subjects who received multiple infusions of the product for sequential HAE attacks (one infusion per attack). Table 1 lists the adverse reactions that occurred in the safety analysis of the open-label extension study in ≥2 subjects or associated with ≥5 HAE attacks during infusion or within 24 hours or 72 hours after the end of a BERINERT infusion. Table 1. Incidence of subjects and HAE Attacks with Adverse Reactions (ARs) Because of the allowance of rescue medication in both study arms, all listed adverse events were considered to be at least potentially related to study medication (e.g., adverse reactions), regardless of the investigator's opinion concerning causality. Starting during Infusion or Within 24 hours or 72 hours after End of an Infusion (Experienced by ≥2 subjects or Associated with ≥5 HAE Attacks Overall) by Preferred Term (Safety subject and HAE Attack Populations) – Open-Label Extension Study Number (%) of subjects (n=57) Number (%) of Attacks (n=1085) Preferred term ARs within 24 hours ARs within 72 hours ARs within 24 hours ARs within 72 hours N = total number of subjects/HAE attacks Data are sorted by decreasing frequency by number of subjects. Any preferred term 13 (22.8%) 20 (35.1%) 27 (2.5%) 41 (3.8%) Headache 2 (3.5%) 4 (7.0%) 3 (0.3%) 6 (0.6%) Nasopharyngitis 1 (1.8%) 2 (3.5%) 1 (<0.1%) 2 (0.2%) Abdominal pain or discomfort 1 (1.8%) 3 (5.3%) 2 (0.2%) 6 (0.6%) Upper respiratory tract infection 0 (0) 1 (1.8%) 0 (0) 1 (<0.1%) Hereditary angioedema attack Hereditary angioedema attacks were only to be reported as adverse reaction if it was a worsening of symptoms during a treated HAE attack. New HAE attacks were not to be reported as adverse reactions. Although the adverse reaction of hereditary angioedema in subject 22301 was a new HAE attack that started after the previous HAE attack had completely resolved, this HAE attack was reported as an adverse reaction, because the HAE attack was not included in the study and treated outside study site with medication other than the study medication. 1 (1.8%) 1 (1.8%) 1 (<0.1%) 1 (<0.1%) Influenza like illness 1 (1.8%) 2 (3.5%) 1 (<0.1%) 2 (0.2%) Rash 2 (3.5%) 2 (3.5%) 2 (0.2%) 2 (0.2%) Vulvovaginal mycotic infection 0 (0) 2 (3.5%) 0 (0) 2 (0.2%) Nausea 1 (1.8%) 1 (1.8%) 4 (0.4%) 5 (0.5%) The incidence and type of adverse reactions with BERINERT when administered for treatment of multiple consecutive acute HAE attacks of any type was similar to those previously observed. As in the placebo-controlled study, no proven cases of infections due to HIV-1/2, HAV, HBV, HCV or Parvovirus B19 were observed during the study. 6.2 Immunogenicity In a post-marketing study forty-six subjects with Type I or Type II HAE were monitored for inhibitory or non-inhibitory antibodies to C1-INH. Blood samples for antibody assessment were taken at Day 1 (First HAE attack requiring administration of a dose of 20 IU/kg IV, baseline value), and at 3, 6 and 9 months. No subjects developed inhibitory antibodies to C1-INH at any of the time points following infusion of BERINERT. Thirteen subjects (28.2%), however, had detectable levels of non-inhibitory Abs at some point during the study, including 9 subjects (19.6%) who had detectable non-inhibitory Abs at baseline. The presence of non-inhibitory anti-C1-INH Abs did not induce apparent immunologically-associated clinical events. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to BERINERT in the studies described above with the incidence of antibodies in other studies or to other products. 6.3 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Adverse reactions reported in Europe since 1979 in patients receiving BERINERT for treatment of HAE include hypersensitivity/anaphylactic reactions, injection-site pain, injection-site redness, chills, and fever. TE Events Associated with HAE Treatment TE events including basilar artery thrombosis, multiple pulmonary microemboli, and thrombosis have been reported with the use of BERINERT at the recommended dose following treatment of HAE. TE Events Associated with Use in Unapproved Indications TE events have also been reported with the use of BERINERT in patients receiving higher than recommended doses during cardiac surgery (unapproved indication) include carotid artery thrombosis, cerebral thrombosis, myocardial infarction, pulmonary embolism, renal vein thrombosis, sagittal sinus thrombosis, inferior vena cava thrombosis, superior vena cava thrombosis, internal jugular vein thrombosis, and peripheral venous thrombosis. 1 The following adverse reactions, identified by system organ class, have been attributed to BERINERT during post-approval use outside the US. Immune System Disorder: Hypersensitivity/anaphylactic reactions, and shock General/Body as a Whole: Pain on injection, redness at injection site, chills, and fever

adverse reactions table

<table width="70%"><caption>Table 1. Incidence of subjects and HAE Attacks with Adverse Reactions (ARs)<footnote>Because of the allowance of rescue medication in both study arms, all listed adverse events were considered to be at least potentially related to study medication (e.g., adverse reactions), regardless of the investigator&apos;s opinion concerning causality.</footnote> Starting during Infusion or Within 24 hours or 72 hours after End of an Infusion (Experienced by &#x2265;2 subjects or Associated with &#x2265;5 HAE Attacks Overall) by Preferred Term (Safety subject and HAE Attack Populations) &#x2013; Open-Label Extension Study</caption><col width="28%" align="left" valign="top"/><col width="18%" align="center" valign="top"/><col width="18%" align="center" valign="top"/><col width="18%" align="center" valign="top"/><col width="18%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule"/><th styleCode="Rrule Botrule" colspan="2">Number (%) of subjects (n=57)</th><th styleCode="Rrule Botrule" colspan="2">Number (%) of Attacks (n=1085)</th></tr><tr styleCode="Botrule"><th styleCode="Lrule Rrule" align="center" valign="middle">Preferred term</th><th styleCode="Rrule" align="center">ARs within 24 hours</th><th styleCode="Rrule">ARs within 72 hours</th><th styleCode="Rrule">ARs within 24 hours</th><th styleCode="Rrule">ARs within 72 hours</th></tr></thead><tfoot><tr><td colspan="5" align="left">N = total number of subjects/HAE attacks</td></tr><tr><td colspan="5" align="left">Data are sorted by decreasing frequency by number of subjects.</td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Any preferred term</content></td><td styleCode="Rrule"><content styleCode="bold">13 (22.8%)</content></td><td styleCode="Rrule"><content styleCode="bold">20 (35.1%)</content></td><td styleCode="Rrule"><content styleCode="bold">27 (2.5%)</content></td><td styleCode="Rrule"><content styleCode="bold">41 (3.8%)</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">2 (3.5%)</td><td styleCode="Rrule">4 (7.0%)</td><td styleCode="Rrule">3 (0.3%)</td><td styleCode="Rrule">6 (0.6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nasopharyngitis</td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">2 (3.5%)</td><td styleCode="Rrule">1 (&lt;0.1%)</td><td styleCode="Rrule">2 (0.2%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Abdominal pain or discomfort</td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">3 (5.3%)</td><td styleCode="Rrule">2 (0.2%)</td><td styleCode="Rrule">6 (0.6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Upper respiratory tract infection</td><td styleCode="Rrule">0 (0)</td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">0 (0)</td><td styleCode="Rrule">1 (&lt;0.1%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Hereditary angioedema attack<footnote>Hereditary angioedema attacks were only to be reported as adverse reaction if it was a worsening of symptoms during a treated HAE attack. New HAE attacks were not to be reported as adverse reactions. Although the adverse reaction of hereditary angioedema in subject 22301 was a new HAE attack that started after the previous HAE attack had completely resolved, this HAE attack was reported as an adverse reaction, because the HAE attack was not included in the study and treated outside study site with medication other than the study medication.</footnote></td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">1 (&lt;0.1%)</td><td styleCode="Rrule">1 (&lt;0.1%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Influenza like illness</td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">2 (3.5%)</td><td styleCode="Rrule">1 (&lt;0.1%)</td><td styleCode="Rrule">2 (0.2%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Rash</td><td styleCode="Rrule">2 (3.5%)</td><td styleCode="Rrule">2 (3.5%)</td><td styleCode="Rrule">2 (0.2%)</td><td styleCode="Rrule">2 (0.2%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Vulvovaginal mycotic infection</td><td styleCode="Rrule">0 (0)</td><td styleCode="Rrule">2 (3.5%)</td><td styleCode="Rrule">0 (0)</td><td styleCode="Rrule">2 (0.2%)</td></tr><tr><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">1 (1.8%)</td><td styleCode="Rrule">4 (0.4%)</td><td styleCode="Rrule">5 (0.5%)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.